Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren

Idr2.6

IDRA-21 – Forschung

Überwiegend Mechanismus / Beobachtung

5 begutachtete Studien

Was die Evidenz sagt

Überwiegend Mechanismus / Beobachtung

Die meisten Studien zu IDRA-21 sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.

Die meiste Evidenz stammt aus gemischt-qualitativen Studien, veröffentlicht 1995–2005.

Basierend auf 5 Studien

Konfidenz

Geringe Konfidenz

Nach Outcome

Learning & memory (ampakine, preclinical only — unproven in humans)Ein Ampakin (positiver allosterischer Modulator des AMPA-Rezeptors), der das Lernen/Gedächtnis ausschließlich bei Tieren und Primaten verbessert; beim Menschen UNBELEGT, ohne Sicherheitsdaten am Menschen und mit einem theoretischen Risiko für Exzitotoxizität/Krampfanfälle. · Nicht etabliert (keine Daten am Menschen)
Überwiegend Mechanismus / Beobachtung5 Studien
Safety profile
Überwiegend Mechanismus / Beobachtung5 Studien
Excitotoxicity & neurotoxicity (theoretical harm)
Überwiegend Mechanismus / Beobachtung3 Studien
Focus & attention (ampakine class, unproven for IDRA-21)Der Nutzen für Fokus/Kognition wird aus der Ampakin-Klasse extrapoliert und ist für IDRA-21 beim Menschen unbelegt; Risiken bezüglich Identität/Reinheit/Dosis vom Graumarkt. · Nicht etabliert (keine Daten am Menschen)
Zu wenige bewertete Studien1 Studie

Ältere Forschungsbasis

Neueste Studie von 2005

199520002005

1Tierstudie1995

IDRA 21 (3 or 5.6 mg/kg p.o.) and aniracetam (30 mg/kg p.o.) administered 60 min before alprazolam ... antagonized the large disruptive effects of alprazolam on learning ... it can be estimated that IDRA 21 is approximately 10-fold more potent than aniracetam ... Very likely IDRA 21 exerts its behavioral effects by antagonizing AMPA receptor desensitization.

Thompson DM, Guidotti A, DiBella M, Costa E. · Proceedings of the National Academy of Sciences of the United States of America (1995)

NON-HUMAN PRIMATE: in patas monkeys, oral IDRA-21 reversed an alprazolam-induced deficit in a repeated-acquisition ('learning') task — the strongest preclinical cognition signal for the compound, but in monkeys, not humans
IDRA-21 was estimated ~10-fold more potent than the prototype ampakine aniracetam at antagonizing the learning deficit, supporting the 'more potent than aniracetam' framing
Had no effect when given alone — it rescued a drug-induced impairment rather than boosting baseline learning, an important nuance for 'nootropic' claims

Quelle ansehen

2Tierstudie1995

(+/-)-IDRA 21 administered orally to rats subjected to a water maze cognition test elicited a performance enhancing effect ... (+)-IDRA 21 was identified as being pharmacologically active in the water maze performance test, whereas (-)-IDRA 21 was completely devoid of activity.

Uzunov DP, Zivkovich I, Pirkle WH, Costa E, Guidotti A. · Journal of Pharmaceutical Sciences (1995)

RODENT: orally administered racemic IDRA-21 enhanced rat water-maze performance — a second, independent animal cognition signal for the compound
Activity resided in the (+)-enantiomer, with the (-)-enantiomer essentially inactive — a stereoselective pharmacology consistent with a defined molecular target rather than a non-specific effect
Frames IDRA-21 as a 'cognition-enhancing benzothiadiazine derivative' and reports the chromatographic resolution of its enantiomers

Quelle ansehen

3In vitro1997

IDRA-21 ... facilitate[s] AMPA receptor function ... while dose dependently, 5-25 microM cyclothiazide in the presence of AMPA is highly neurotoxic, IDRA-21 (up to 100 microM) is devoid of neurotoxicity ... IDRA-21 is a potent cognition-enhancing drug virtually devoid of neurotoxic liability because it acts as a partial negative allosteric modulator of AMPA receptor desensitization.

Impagnatiello F, Oberto A, Longone P, Costa E, Guidotti A. · Proceedings of the National Academy of Sciences of the United States of America (1997)

IN-VITRO MECHANISM: in cultured rat cerebellar granule neurons, IDRA-21 facilitated AMPA-receptor function by slowing desensitization, raising intracellular Na+ and Ca2+ — direct evidence of the ampakine mechanism
Acted as a 'partial' modulator with lower intrinsic activity and shorter-lasting Ca2+ transients than cyclothiazide — a key reason its safety margin appears wider
CRITICAL SAFETY NUANCE: the related stronger modulator cyclothiazide was overtly neurotoxic at 5-25 microM, whereas IDRA-21 was devoid of neurotoxicity up to 100 microM — so excitotoxicity is a real, dose- and compound-dependent hazard of the class, not eliminated

Quelle ansehen

4Übersicht2005

Positive AMPA modulators enhance glutamate transmission via the AMPA receptor by altering the rate of desensitization; alone they have no intrinsic activity ... they were first studied in models of short- and long-term memory ... In general, these agents were procognitive.

Black MD. · Psychopharmacology (Berlin) (2005)

CLASS REVIEW (PRECLINICAL): situates IDRA-21 within the positive-AMPA-modulator ('ampakine') class, which enhances glutamate transmission by slowing desensitization and is generally procognitive in animal memory models
Explains that effects depend on AMPA-receptor subunit composition and that the class also shows preclinical signals in schizophrenia, depression, neuroprotection and Parkinson's models
Explicitly a review of PRECLINICAL data — it characterises class potential, not demonstrated human efficacy or safety for IDRA-21

Quelle ansehen

5In vitro1998

The increase on the expression of GluR1 FLIP and FLOP and of GluR4 FLOP mRNA variants during development is associated with a 10-fold increase in AMPA-mediated Na+ currents and in the increased amplification of this current by ... IDRA21 or by ... cyclothiazide.

Longone P, Impagnatiello F, Mienville JM, Costa E, Guidotti A. · Journal of Molecular Neuroscience (1998)

IN-VITRO MECHANISM: links IDRA-21's amplification of AMPA-mediated Na+ currents to specific AMPA-receptor splice variants (GluR1/GluR4 FLIP/FLOP) in maturing cerebellar granule cells
Shows the magnitude of IDRA-21's effect depends on AMPA-receptor subunit/splice-variant composition — a determinant of where and how strongly an ampakine acts
Reinforces the molecular ampakine mechanism underlying the animal cognition findings, at receptor-pharmacology level

Quelle ansehen

In der Forschungsbibliothek ansehen

IDRA-21 – Forschung

Überwiegend Mechanismus / Beobachtung

7-Chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine S,S-dioxide (IDRA 21), a congener of aniracetam, potently abates pharmacologically induced cognitive impairments in patas monkeys.

Enantiomeric resolution with a new chiral stationary phase of 7-chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine S,S-dioxide, a cognition-enhancing benzothiadiazine derivative.

7-Chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine S,S-dioxide: a partial modulator of AMPA receptor desensitization devoid of neurotoxicity.

Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits. A review of preclinical data.

Changes in AMPA receptor-spliced variant expression and shift in AMPA receptor spontaneous desensitization pharmacology during cerebellar granule cell maturation in vitro.